Cipla gets USFDA observations for its Goa facility
New Delhi: Drug firm Cipla on Wednesday said it has received observations from the USFDA for its Goa manufacturing facility. It further said that the developments will not have any material impact on the company's US business at this stage.
"The United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI). The company does not believe that this will have any material impact on the US business at this stage," the drug major said in an exchange filing.
Read also: Japanese financial group MUFG sells 2.10pc shares in Cipla
Cipla further said it has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd